ScripThe so-called "neglected diseases" affect some of the world's poorest people. In many cases, the cost of controlling these diseases is tiny in comparison with the benefits their eradication would brin
ScripVioQuest Pharmaceuticals is running out of cash and it says it needs funds immediately; it has confirmed that its CEO and chief financial officer have threatened to resign. During the past year, Vi
ScripSpurred by Gates money, biotech global health R&D is gaining traction, but a growth model remains elusive. By Marc Wortman Medicines to fight significant global health problems are scarce because the
ScripThe US biopharmaceutical company Arno Therapeutics has named Brian Lenz chief financial officer. He has more than 10 years' financial and operational management experience, having previously served as